| Coronary Artery Disease

Brilinta vs Katerzia

Side-by-side clinical, coverage, and cost comparison for coronary artery disease.

Deep comparison between: Brilinta vs Katerzia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKaterzia has a higher rate of injection site reactions vs Brilinta based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Katerzia but not Brilinta, including UnitedHealthcare

Category

Brilinta

Katerzia

At A Glance

RouteOral

FrequencyTwice daily

ClassP2Y12 platelet inhibitor

RouteOral

FrequencyDaily

ClassCalcium channel blocker

Indications

Acute Coronary Syndrome
Myocardial Infarction
Coronary Artery Disease
Acute Ischemic Stroke
Transient Ischemic Attack
Stent thrombosis

Hypertensive disease
Stable angina
Angina Pectoris, Variant
Coronary Artery Disease

Dosing

Acute Coronary Syndrome, Myocardial Infarction, Stent thrombosis 180 mg oral loading dose, then 90 mg twice daily for the first year; after one year, 60 mg twice daily; use with aspirin 75-100 mg daily.

Coronary Artery Disease 60 mg twice daily; use with aspirin 75-100 mg daily.

Acute Ischemic Stroke, Transient Ischemic Attack 180 mg loading dose, then 90 mg twice daily for up to 30 days; use with aspirin 300-325 mg loading dose and 75-100 mg daily maintenance.

Hypertensive disease (adults) 5 mg orally once daily (max 10 mg); start 2.5 mg in small, fragile, elderly patients, or those with hepatic insufficiency.

Hypertensive disease (pediatric, ages 6-17) 2.5-5 mg orally once daily; doses >5 mg have not been studied in pediatric patients.

Stable angina, Angina Pectoris, Variant 5-10 mg orally once daily; lower dose suggested in elderly and patients with hepatic insufficiency; most patients require 10 mg.

Coronary Artery Disease 5-10 mg orally once daily; majority of patients required 10 mg in clinical studies.

Contraindications

History of intracranial hemorrhage
Active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage)
Hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product

Known sensitivity to amlodipine

Drug Interactions

785View drug interactions

1162View drug interactions

Adverse Reactions

Most common (>=4%) Dyspnea, dizziness, nausea, bleeding

Serious Major bleeding, fatal/life-threatening bleeding, intracranial hemorrhage, bradycardia, ventricular pauses

Postmarketing Thrombotic Thrombocytopenic Purpura, hypersensitivity reactions including angioedema, central sleep apnea, Cheyne-Stokes respiration, rash

Most common (>1%) edema, dizziness, flushing, palpitation, fatigue, nausea, abdominal pain, somnolence

Postmarketing gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder

Pharmacology

P2Y12 platelet inhibitor; ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation, with ticagrelor and its active metabolite being approximately equipotent.

Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation, reduction in peripheral vascular resistance, and reduction in blood pressure.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Brilinta